跳至主要内容
临床试验/NCT00201786
NCT00201786已完成2 期

Phase II Trial of Pentostatin in Steroid Refractory Acute Graft Versus Host Disease

Ohio State University Comprehensive Cancer Center1 个研究点 分布在 1 个国家目标入组 8 人开始时间: 2003年7月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
状态
已完成
入组人数
8
试验地点
1
主要终点
Evaluate the response rate (complete and partial) to treatment with pentostatin in steroid-refractory acute GVHD (graft-versus-host disease).

研究概览

简要总结

This study will evaluate the response rate to treatment with pentostatin in steroid-refractory acute graft versus host disease.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Must have biopsy proven grade II-IV acute GVHD refractory to systemic corticosteroids
  • No chronic GVHD
  • Age ≥ 18 years
  • Evidence of myeloid engraftment (ANC ≥ 0.5 x 109/l)
  • Performance status 0-3

排除标准

  • Patients on mechanical ventilation or who have resting O2 saturation <90% by pulse-oximetry.
  • Patients on renal dialysis or who have an estimated creatinine clearance of < 30 ml/min/1.73 m
  • Patients with documented clinical infection (progressive symptoms despite antibiotics or continued fever) cannot be enrolled on study until infection is controlled.

研究组 & 干预措施

Pentostatin

Experimental

Pentostatin is given at a dose of 1.5 mg/m2/day IV x 3 consecutive days. Each IV infusion of pentostatin will be administered over 20-30 minutes in 100-250 ml of D5W or NS.

干预措施: Pentostatin (Drug)

结局指标

主要结局

Evaluate the response rate (complete and partial) to treatment with pentostatin in steroid-refractory acute GVHD (graft-versus-host disease).

时间窗: up to 2 years

次要结局

  • Investigate the pharmacokinetics of pentostatin in patients with acute GVHD to correlate the response with area under the curve (AUC).(up to 2 years)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Craig Hofmeister

Principal Investigator

Ohio State University Comprehensive Cancer Center

研究点 (1)

Loading locations...

相似试验